Home/Filings/4/0001214659-22-011124
4//SEC Filing

Wasoff Evan L 4

Accession 0001214659-22-011124

CIK 0001625288other

Filed

Sep 13, 8:00 PM ET

Accepted

Sep 14, 5:42 PM ET

Size

10.0 KB

Accession

0001214659-22-011124

Insider Transaction Report

Form 4
Period: 2022-04-20
Wasoff Evan L
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2022-07-27+250,0003,250,000 total
  • Award

    Common stock

    2022-04-20+250,0003,000,000 total
Holdings
  • Options to purchase common stock (right to buy)

    Exercise: $0.54From: 2018-07-25Exp: 2025-07-25common stock (420,000 underlying)
    420,000
  • Options to purchase common stock (right to buy)

    Exercise: $0.08From: 2020-08-19Exp: 2027-08-19common stock (1,500,000 underlying)
    1,500,000
  • Options to purchase common stock (right to buy)

    Exercise: $0.66From: 2018-10-26Exp: 2025-10-26common stock (200,000 underlying)
    200,000
Footnotes (1)
  • [F1]Issued in lieu of compensation for services.

Issuer

NEXIEN BIOPHARMA, INC.

CIK 0001625288

Entity typeother

Related Parties

1
  • filerCIK 0001719738

Filing Metadata

Form type
4
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 5:42 PM ET
Size
10.0 KB